Glendale, CA14 Active Studies

Lung Cancer Clinical Trials in Glendale, CA

Find 14 actively recruiting lung cancer clinical trials in Glendale, CA. Connect with local research sites and explore new treatment options.

14
Active Trials
11
Sponsors
5,658
Enrolling

Recruiting Lung Cancer Studies in Glendale

RecruitingGlendale, CANCT05502237

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemot...

1,069 participants
Gilead Sciences
View Study Details
RecruitingGlendale, CANCT06692738

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squam...

880 participants
AstraZeneca
View Study Details
RecruitingGlendale, CANCT06564844

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgic...

660 participants
AstraZeneca
View Study Details
RecruitingGlendale, CANCT06667076

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth f...

480 participants
Janssen Research & Development, LLC
View Study Details
RecruitingGlendale, CANCT06745908

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enro...

460 participants
ImmunityBio, Inc.
View Study Details
RecruitingGlendale, CANCT06765109

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with...

450 participants
Nuvalent Inc.
View Study Details
RecruitingGlendale, CANCT06151574

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any...

416 participants
Boehringer Ingelheim
View Study Details
RecruitingGlendale, CANCT05668988

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastati...

320 participants
Dizal Pharmaceuticals
View Study Details
RecruitingGlendale, CANCT06120140

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 dermatologic adverse events of interest (DAEIs) when co...

300 participants
Janssen Research & Development, LLC
View Study Details
RecruitingGlendale, CANCT05468489

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Sub...

200 participants
Shanghai Henlius Biotech
View Study Details
RecruitingGlendale, CANCT06173505

Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of ca...

168 participants
Xencor, Inc.
View Study Details
RecruitingGlendale, CANCT05168566

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, ...

99 participants
Teligene US
View Study Details
RecruitingGlendale, CANCT05609578

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with a...

90 participants
Mirati Therapeutics Inc.
View Study Details
RecruitingGlendale, CANCT06010329

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutat...

66 participants
Teligene US
View Study Details

About Lung Cancer Clinical Trials in Glendale

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 14 lung cancer clinical trials recruiting participants in Glendale, CA. These studies are seeking a combined 5,658 participants. Research is being sponsored by Gilead Sciences, AstraZeneca, Janssen Research & Development, LLC and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Glendale — FAQ

Are there lung cancer clinical trials in Glendale?

Yes, there are 14 lung cancer clinical trials currently recruiting in Glendale, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Glendale?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Glendale research site will contact you about next steps.

Are clinical trials in Glendale free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Glendale studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 14 active trials in Glendale are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated March 2, 2026 from ClinicalTrials.gov